FOXP3 and neutropenia: There were no serious infectious AEs, no cases of neutropenia and no significant effects on peripheral T helper–lymphocyte subsets (Th1, Th17), except for a small increase in CD25high/CD127low/Foxp3+ regulatory T cells in the highest-dose group at Week 12 (4.9% at screening vs 5.8% at Week 12; P = 0.0002) (Fig. S4).